Evolving Important Role of Lutetium-177 for Therapeutic Nuclear Medicine
Lutetium-177 (177Lu) is a late entrant into the nuclear medicine therapy arena but is expected to become one of the most widely used therapeutic radionuclides. This paper analyses the reason for the increasing preference of 177Lu as a therapeutic radionuclide. While the radionuclidic
properties favor its use for several therapeutic applications, the potential for large scale production of 177Lu is also an important aspect for its acceptability as a therapeutic radionuclide. This introductory discussion also summarizes some developing clinical uses and suggested future
directions for applications of 177Lu.
Keywords: Antibodies; Lutetium-177; bone pain palliation; isotope production; peptides; targeted radionuclide therapy; therapeutic radiopharmaceuticals
Document Type: Research Article
Publication date: 01 August 2015
- Current Radiopharmaceuticals publishes original research articles, letters, reviews, drug clinical trial studies and guest edited issues on all aspects of research and development of radiolabelled compound preparations. The scope of the journal covers the following areas: radio imaging techniques, therapies; preparation and application of radionuclide compounds including the incorporation of tracer methods used in scientific research and applications.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content